ArticleBMC cancer2013
Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer.
Article in BMC cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Biomarker concordance between primary colorectal cancer and its metastases.EBioMedicine · 2019Pooled it
- p53 protein degradation redefines the initiation mechanisms and drives transitional mutations in colorectal cancer.Nature communications · 2025Article
- Casein Kinase 1α-A Target for Prostate Cancer Therapy?Cancers · 2024Review
- Ring finger protein 19A is overexpressed in non-small cell lung cancer and mediates p53 ubiquitin-degradation to promote cancer growth.Journal of cellular and molecular medicine · 2021Article
- Biomarkers (mRNAs and Non-Coding RNAs) for the Diagnosis and Prognosis of Colorectal Cancer - From the Body Fluid to Tissue Level.Frontiers in oncology · 2021Review
- Application of phototherapeutic-based nanoparticles in colorectal cancer.International journal of biological sciences · 2021Review
- Functions and regulation of the serine/threonine protein kinase CK1 family: moving beyond promiscuity.The Biochemical journal · 2020Review
- Article
- Article
- Casein kinase 1α: biological mechanisms and theranostic potential.Cell communication and signaling : CCS · 2018Review
- Methylation Status of Transcriptional Modulatory Genes Associated with Colorectal Cancer in Northeast China.Gut and liver · 2018Article
- MICAL2 Mediates p53 Ubiquitin Degradation through Oxidating p53 Methionine 40 and 160 and Promotes Colorectal Cancer Malignance.Theranostics · 2018Article
- Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.Cancer drug resistance (Alhambra, Calif.) · 2018Article
- Two Active Compounds fromAdvanced pharmaceutical bulletin · 2017Article
- The association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery.Oncology letters · 2017Article
- Grape compounds suppress colon cancer stem cells in vitro and in a rodent model of colon carcinogenesis.BMC complementary and alternative medicine · 2016Article
- P53 Is Involved in a Three-Dimensional Architecture-Mediated Decrease in Chemosensitivity in Colon Cancer.Journal of Cancer · 2016Article
- The Genetic Architecture of Murine Glutathione Transferases.PloS one · 2016Article
- Stress-induced DNA damage biomarkers: applications and limitations.Frontiers in chemistry · 2015Review
- Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis.Molecular cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundp53 (encoded by TP53) is involved in DNA damage repair, cell cycle regulation, apoptosis, aging and cellular senescence. TP53 is mutated in around 50% of human cancers. Nevertheless, the consequences of p53 inactivation in colon cancer outcome remain unclear. Recently, a new role of p53 together with CSNK1A1 in colon cancer invasiveness has been described in mice.
methodsBy combining data on different levels of p53 inactivation, we aimed to predict p53 functionality and to determine its effects on colon cancer outcome. Moreover, survival effects of CSNK1A1 together with p53 were also studied.Eighty-three formalin fixed paraffin embedded colon tumors were enriched for tumor cells using flow sorting, the extracted DNA was used in a custom SNP array to determine chr17p13-11 allelic state; p53 immunostaining, TP53 exons 5, 6, 7 and 8 mutations were determined in combination with mRNA expression analysis on frozen tissue.
resultsPatients with a predicted functional p53 had a better prognosis than patients with non functional p53 (Log Rank p=0.009). Expression of CSNK1A1 modified p53 survival effects. Patients with low CSNK1A1 expression and non-functional p53 had a very poor survival both in the univariate (Log Rank p<0.001) and in the multivariate survival analysis (HR=4.74 95% CI 1.45 - 15.3 p=0.009).
conclusionThe combination of mutational, genomic, protein and downstream transcriptional activity data predicted p53 functionality which is shown to have a prognostic effect on colon cancer patients. This effect was specifically modified by CSKN1A1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.